A5041098418- Cancer Immunotherapy and Biomarkers
- Immune cells in cancer
- Immunotherapy and Immune Responses
- Cancer, Hypoxia, and Metabolism
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- CAR-T cell therapy research
- Medical Imaging Techniques and Applications
- Radiopharmaceutical Chemistry and Applications
- Systemic Lupus Erythematosus Research
- Systemic Sclerosis and Related Diseases
- Erythrocyte Function and Pathophysiology
- Inflammatory Myopathies and Dermatomyositis
- Blood groups and transfusion
- Mesenchymal stem cell research
- Complement system in diseases
- Hematopoietic Stem Cell Transplantation
- Cancer Cells and Metastasis
- Monoclonal and Polyclonal Antibodies Research
- vaccines and immunoinformatics approaches
Radboud University Medical Center
2013-2021
Radboud University Nijmegen
2013-2021
Radboud Institute for Molecular Life Sciences
2019-2021
Karolinska Institutet
2014-2015
National University Hospital of Iceland
2004
Reykjavík University
2004
Plasmacytoid dendritic cells (PDCs) are a critical source of type I interferons (IFNs) that can contribute to the onset and maintenance autoimmunity. Molecular mechanisms leading PDC dysregulation persistent IFN signature largely unexplored, especially in patients with systemic sclerosis (SSc), disease which PDCs infiltrate fibrotic skin lesions produce higher levels IFNα than those healthy controls. This study was undertaken investigate potential microRNA (miRNA)-mediated epigenetic...
The superiority of dendritic cells (DCs) as antigen-presenting has been exploited in numerous clinical trials, where generally monocyte-derived DCs (Mo-DCs) are injected to induce immunity patients with cancer or infectious diseases. Despite promising expansion antigen-specific T cells, the responses following vaccination have limited, indicating that further improvements DC vaccine potency necessary. Pre-clinical studies suggest combination primary subsets, such myeloid and plasmacytoid...
Objective: We report the characterization of MCLA-117, a novel T cell-redirecting antibody for acute myeloid leukaemia (AML) treatment targeting CD3 on cells and CLEC12A leukaemic cells. In AML, is expressed blasts stem cells.Methods: The functional capacity MCLA-117 to redirect resting eradicate CLEC12APOS tumor was studied using human samples, including primary AML samples.Results: Within normal hematopoietic compartment, binds expressing but not early progenitors or induces cell...
Abstract Potent immunotherapies are urgently needed to boost antitumor immunity and control disease in cancer patients. As dendritic cells (DCs) the most powerful APCs, they an attractive means reinvigorate T cell responses. An appealing strategy use effective Ag processing presentation machinery, stimulation cross-talk capacity of natural DC subsets is vivo tumor delivery. In this context, endocytic C-type lectin receptors targeting molecules. study, we investigated whether CLEC12A...
Abstract Antibodies that block the interaction between programmed death ligand 1 (PD-L1) and PD-1 have shown impressive responses in subgroups of patients with cancer. PD-L1 expression tumors seems to be a prerequisite for treatment response. However, is heterogeneously expressed within tumor lesions may change upon disease progression treatment. Imaging could aid patient selection. Previously, we showed feasibility image PD-L1+ immunodeficient mice. also on immune cell subsets. Therefore,...
Early natural killer (NK)-cell repopulation after allogeneic stem cell transplantation (allo-SCT) has been associated with reduced relapse rates without an increased risk of graft-versus-host disease, indicating that donor NK cells have specific antileukemic activity. Therefore, adoptive transfer is attractive strategy to reduce allo-SCT. Since origin will not be rejected, multiple NK-cell infusions could administered in this setting. However, isolation high numbers functional from...
Abstract Rheumatoid arthritis (RA) is associated with amino acid variants in multiple MHC molecules. The association to class II (MHC-II) has been studied several animal models of RA. In most cases these depend on T cells restricted a single immunodominant peptide the immunizing Ag, which does not resemble autoreactive An exception pristane-induced (PIA) rat where polyclonal induce chronic after being primed against endogenous Ags. this study, we used mixed genetic and functional approach...
Because of the potent graft-versus-tumor (GVT) effect, allogeneic stem cell transplantation (alloSCT) can be a curative therapy for hematological malignancies. However, relapse remains most frequent cause treatment failure, illustrating necessity development adjuvant post-transplant therapies to boost GVT immunity. Dendritic (DC) vaccination is promising strategy in this respect, particular, where distinct biologic functions naturally occurring DC subsets, i.e. myeloid DCs (mDCs) and...
Abstract Allogeneic stem cell transplantation (alloSCT), following induction chemotherapy, can be curative for hemato-oncology patients due to powerful graft-versus-tumor immunity. However, disease recurrence remains the major cause of treatment failure, emphasizing need potent adjuvant immunotherapy. In this regard, dendritic (DC) vaccination is highly attractive, as DCs are key orchestrators innate and adaptive Natural DC subsets postulated more compared with monocyte-derived DCs, their...
Genetic variation in the major histocompatibility complex (MHC) affects CD4∶CD8 lineage commitment and MHC expression. However, contribution of specific genes this gene-dense region has not yet been resolved. Nor it established whether same regulate expression T cell selection. Here, we assessed impact natural genetic on using two models rat. First, mapped Quantitative Trait Loci (QTLs) associated with class I II protein ratio outbred Heterogeneous Stock rats. We identified 10 QTLs across...
Autologous, patient-specific, monocyte-derived dendritic cell (MoDC) vaccines have been successfully applied in the clinical studies so far. However, routine application of this strategy has hampered by difficulties generating sufficient numbers DC and poor vaccine quality because pathology or prior treatment received patients. The immunotherapeutic potential other subsets not thoroughly investigated their rarity tissues associated with ex vivo generation. high expansion differentiation...
This study was conducted to investigate the frequency and origin of discrepant assay results between two haemolytic assays which both measure activity classical pathway complement (CH50) by haemolysis sheep red blood cells (SRBCs). One is in gel phase using undiluted sera other liquid with 1/100 dilution. The majority readings are observed as low or absent phase, values within above normal range phase. incidence evaluated 300 samples. Furthermore, 28 samples showing most were investigated...
<p>Supplemental Figure 1</p>
<p>Supplemental Table 1</p>
<p>Supplemental Table 2</p>
<p>Supplemental Figure 3</p>
<p>Supplemental Figure 2</p>
<div>Abstract<p>Antibodies that block the interaction between programmed death ligand 1 (PD-L1) and PD-1 have shown impressive responses in subgroups of patients with cancer. PD-L1 expression tumors seems to be a prerequisite for treatment response. However, is heterogeneously expressed within tumor lesions may change upon disease progression treatment. Imaging could aid patient selection. Previously, we showed feasibility image PD-L1<sup>+</sup> immunodeficient mice....
<p>Supplemental Figure 3</p>
<p>Supplemental Table 1</p>
<p>Supplemental Table 2</p>
<p>Supplemental Figure 1</p>
<p>Supplemental Figure 2</p>
<div>Abstract<p>Antibodies that block the interaction between programmed death ligand 1 (PD-L1) and PD-1 have shown impressive responses in subgroups of patients with cancer. PD-L1 expression tumors seems to be a prerequisite for treatment response. However, is heterogeneously expressed within tumor lesions may change upon disease progression treatment. Imaging could aid patient selection. Previously, we showed feasibility image PD-L1<sup>+</sup> immunodeficient mice....